Oral immunoglobulin induces mononuclear cell apoptosis in patients suffering from idiopathic chronic pain syndrome: results from a pilot study.
OBJECTIVE
The objective of this clinical pilot study was to examine the induction of apoptosis in mononuclear cells on treatment of patients with chronic pain syndrome with oral immunoglobulin produced from bovine colostrum (BCC).


METHODS
The 4 patients suffering from chronic idiopathic pain (idiopathic facial pain, CRPS or fibromyalgia) who were enrolled in the study had previously successfully been treated with BCC (varying individual doses). Mononuclear cells from peripheral blood were analyzed for representative cytokines in the serum as well as by TUNEL-assay to detect apoptotic cellular events 14 days after the last treatment with BCC and 14 days after restarting the treatment protocol with BCC. The clinical response (pain and quality of life parameters using a visual analogue scale (VAS)) were determined regularly in each patient.


RESULTS
The findings showed a disturbed apoptosis homeostasis in 3 of the 4 patients. These results were accompanied by a relief of the pain symptoms. The 4th patient was found not to need any further analgetic treatment since she demonstrated only nonsignificant changes in her laboratory screening and immunological parameters and by the end of the study she was also completely free of pain (long-term treatment with BCC).


CONCLUSIONS
In spite of the low patient number, the results were obtained with a sufficiently high degree of control because of the study design. The agreement of the clinical data with our laboratory measurements suggests that the induction of apoptotic events in mononuclear cells is the result of the dominant immunological effects of BCC treatment.
Waaga-Gasser
A M
AM
Department of Surgery I, Molecular Oncology and Immunology, University of Wuerzburg, Germany.
Gasser
M
M
Stock
M
M
Grimm
M
M
Sprotte
G
G
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000818:Animals; D017209:Apoptosis; D002417:Cattle; D002648:Child; D002908:Chronic Disease; D003126:Colostrum / Q000276:immunology; D020918:Complex Regional Pain Syndromes / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D005156:Facial Neuralgia / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D005260:Female; D005356:Fibromyalgia / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D006785:Hospitals, University; D006801:Humans; D007136:Immunoglobulins / Q000008:administration & dosage / Q000627:therapeutic use*; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D007963:Leukocytes, Mononuclear / Q000276:immunology* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011788:Quality of Life
D007136:Immunoglobulins; D007334:Insulin-Like Growth Factor I